Rezdiffra: Data from P3 MAESTRO-NASH-OUTCOMES trial (NCT05500222) in participants with well-compensated NASH in 2027 (Madrigal Pharmaceuticals) - Feb 27, 2025 - Q4 2024 Results
P3 data • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis
|